Pure Global AI
NCT06213324Recruiting

Neural Circuit Effects of Ketamine in Depression

Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI
Icahn School of Medicine at Mount SinaiPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
Ketamine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Icahn School of Medicine at Mount Sinai
Location
New York, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Jan 31, 2024
End date
Apr 30, 2028
Enrollment
120 participants
Primary outcome

sgACC response to the Incentive Flanker Task

Summary

This project is designed to examine the role of the subgenual anterior cingulate cortex
 (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and
 sustained effects of ketamine on agACC activation and depression symptoms.

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06213324
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06213324 through Pure Global AI's free database. This Phase 4 trial is sponsored by Icahn School of Medicine at Mount Sinai and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.